Slug contributes to gemcitabine resistance through epithelial-mesenchymal transition in CD133+ pancreatic cancer cells

详细信息    查看全文

• 作者：Koichiro Tsukasa ; Qiang Ding ; Makoto Yoshimitsu ; Yumi Miyazaki…
• 关键词：Pancreatic cancer ; Slug ; CD133 ; Chemoresistance ; Gemcitabine
• 刊名：Human Cell
• 出版年：2015
• 出版时间：October 2015
• 年：2015
• 卷：28
• 期：4
• 页码：167-174
• 全文大小：1,743 KB
• 参考文献：1.Jemal A, Siegel R, Ward E, et al. Cancer statistics. 2008. CA Cancer J Clin. 2008;58:71鈥?6.CrossRef PubMed
  2.Takao S, Ding Q, Matsubara S. Pancreatic cancer stem cells: regulatory networks in the tumor microenvironment and targeted therapy. J Hepatobiliary Pancreat Sci. 2012;19:614鈥?0.CrossRef PubMed
  3.Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030鈥?.CrossRef PubMed
  4.Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313鈥?3.CrossRef PubMed
  5.Maeda S, Shinchi H, Kurahara H, et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer. 2008;98:1389鈥?7.PubMed Central CrossRef PubMed
  6.Mjaatvedt CH, Markwald RR. Induction of an epithelial-mesenchymal transition by an in vivo adheron-like complex. Dev Biol. 1989;136:118鈥?8.CrossRef PubMed
  7.Thompson EW, Torri J, Sabol M, et al. Oncogene-induced basement membrane invasiveness in human mammary epithelial cells. Clin Exp Metastasis. 1994;12:181鈥?4.CrossRef PubMed
  8.Rosivatz E, Becker I, Specht K, et al. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol. 2002;161:1881鈥?1.PubMed Central CrossRef PubMed
  9.Arumugam T, Ramachandran V, Fournier KF, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69:5820鈥?.PubMed Central CrossRef PubMed
  10.Wang Z, Li Y, Kong D, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009;69:2400鈥?.PubMed Central CrossRef PubMed
  11.Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003;15:740鈥?.CrossRef PubMed
  12.Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871鈥?0.CrossRef PubMed
  13.Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119:1429鈥?7.PubMed Central CrossRef PubMed
  14.Mancini M, Petta S, Iacobucci I, Salvestrini V, Barbieri E, Santucci MA. Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells. Cell Signal. 2010;22:1247鈥?3.CrossRef PubMed
  15.Guo Y, Zi X, Koontz Z, et al. Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res. 2007;25:964鈥?1.CrossRef PubMed
  16.Jethwa P, Naqvi M, Hardy RG, et al. Overexpression of Slug is associated with malignant progression of esophageal adenocarcinoma. World J Gastroenterol. 2008;14:1044鈥?2.PubMed Central CrossRef PubMed
  17.Come C, Magnino F, Bibeau F, et al. Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res. 2006;12:5395鈥?02.CrossRef PubMed
  18.Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403鈥?3.PubMed
  19.Moore MJ, Goldstein D, Hamm J, et al. National Cancer Institute of Canada Clinical Trials, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960鈥?.CrossRef PubMed
  20.Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817鈥?5.CrossRef PubMed
  21.Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691鈥?03.CrossRef
  22.Ding Q, Yoshimitsu M, Kuwahata T, et al. Establishment of a highly migratory subclone reveals that CD133 contributes to migration and invasion through epithelial-mesenchymal transition in pancreatic cancer. Hum Cell. 2012;25:1鈥?.CrossRef PubMed
  23.Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415鈥?8.CrossRef PubMed
  24.Ding Q, Miyazaki Y, Tsukasa K, Matsubara S, Yoshimitsu M, Takao S. CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis. Mol Cancer. 2014;13:15.PubMed Central CrossRef PubMed
  25.Yang AD, Fan F, Camp ER, et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006;12:4147鈥?3.CrossRef PubMed
  26.Quint K, Tonigold M, Di Fazio P, et al. Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition. Int J Oncol. 2012;41:2093鈥?02.PubMed
  27.Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 2007;67:1979鈥?7.CrossRef PubMed
  28.Kajiyama H, Shibata K, Terauchi M, et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol. 2007;31:277鈥?3.PubMed
  29.Kurrey NK, Jalgaonkar SP, Joglekar AV, et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells. 2009;27:2059鈥?8.CrossRef PubMed
  30.Haslehurst AM, Koti M, Dharsee M, et al. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer. 2012;12:91.PubMed Central CrossRef PubMed
  31.Tamura D, Arao T, Nagai T, et al. Slug increases sensitivity to tubulin-binding agents via the downregulation of betaIII and betaIVa-tubulin in lung cancer cells. Cancer Med. 2013;2:144鈥?4.PubMed Central CrossRef PubMed
  32.Reshmi G, Sona C, Pillai MR. Comprehensive patterns in microRNA regulation of transcription factors during tumor metastasis. J Cell Biochem. 2011;112:2210鈥?.CrossRef PubMed
  33.Wang J, Haubrock M, Cao KM, et al. Regulatory coordination of clustered microRNAs based on microRNA-transcription factor regulatory network. BMC Syst Biol. 2011;5:199.PubMed Central CrossRef PubMed
  34.Moes M, Le Bechec A, Crespo I, et al. A novel network integrating a miRNA-203/SNAI1 feedback loop which regulates epithelial to mesenchymal transition. PLoS ONE. 2012;7:e35440.PubMed Central CrossRef PubMed
  35.Liu YN, Yin JJ, Abou-Kheir W, et al. MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene. 2013;32:296鈥?06.CrossRef PubMed
  36.Bracken CP, Gregory PA, Kolesnikoff N, et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008;68:7846鈥?4.CrossRef PubMed
  
• 作者单位：Koichiro Tsukasa (1)
  Qiang Ding (1) (2)
  Makoto Yoshimitsu (3)
  Yumi Miyazaki (1)
  Shyuichiro Matsubara (1)
  Sonshin Takao (1)
  
  1. Division of Cancer and Regenerative Medicine, Frontier Biomedical Science and Swine Research Center, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan
  2. Keenan Research Centre of the Li Ka Shing Knowledge Institute of St. Michael鈥檚 Hospital, Tronto, Canada
  3. Department of Hematology and Immunology, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan
  
• 刊物主题：Cell Biology; Embryology; Oncology; Stem Cells; Reproductive Medicine; Cell Culture;
• 出版者：Springer Japan
• ISSN：1749-0774

文摘

CD133-positive pancreatic cancer is correlated with unfavorable survival despite current development of therapy. Slug acts as a master regulator of epithelial-mesenchymal transition (EMT) which is the essential process in cancer progression. The aim of this study was to investigate the role of Slug in gemcitabine treatment for CD133-positive pancreatic cancer cells. We used a previously established pancreatic cancer cell line expressing high level of CD133 (Capan-1M9), which also expresses high level of Slug. We generated Slug knock-down subclone (shSlug M9) from this cell line, and compared expression of EMT-related genes, migration, invasion and gemcitabine resistance between two cell lines. Slug knock-down in CD133-positive pancreatic cancer cell line led to the reduction of migration and invasion ability. Furthermore, Slug knock-down sensitized CD133-positive pancreatic cancer cell line to gemcitabine. These results suggest that Slug plays an important role in not only invasion ability through EMT but also gemcitabine resistance of CD133-positive pancreatic cancer cells. Keywords Pancreatic cancer Slug CD133 Chemoresistance Gemcitabine